Popular Articles

Acucela's Novel Visual Cycle Modulator Demonstrates Promise As A Treatment For Dry Age-Related Macular Degeneration
Acucela, a clinical-stage biotechnology company focused on developing new treatments for blinding eye diseases, announced today that data on the company"s novel visual cycle modulator, ACU-4429, a potential oral treatment for dry age-related macular degeneration (AMD), will be featured at the Aegean Retina XI Meeting being held in Crete, Greece from July 3 to 5, 2009. Dry AMD is a leading cause of vision loss in people over the age of 50, yet there are no therapies currently approved to treat this condition.
generic viagra online
CDC Report Examines Sexual Health, AIDS Rates Among U.S. Teenagers, Young Adults
CDC"s latest Morbidity and Mortality Weekly Report (MMWR) examines the sexual health of young adults and teenagers in the U.S., Reuters reports. "The data presented in this report indicate that many young persons in the United States engage in sexual risk behavior and experience negative reproductive health outcomes," the MMWR states (7/16). For the report, CDC compiled data from several different studies involving hundreds of thousands of teenagers and young adults age 10 to 25. Among other findings, the data indicated that AIDS rates among boys age 15 to 19 increased from 1.3 cases per 100,000 in 1997 to 2.5 cases in 2006. The report also said that new HIV and AIDS diagnoses were highest among young blacks across all age groups (Chicago Tribune, 7/17). Kevin Fenton, director of CDC"s National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention, said, "It is imperative that all of us at the national and community level work together to ensure STD and HIV prevention programs are reaching young people, particularly in communities with the greatest burden of disease" (Brewington, "Picture of Health," Baltimore Sun, 7/16).
News of the day
Eiger BioPharmaceuticals Acquires Exclusive License To Novel Hepatitis C Virus (HCV) Technology From Stanford University
Eiger BioPharmaceuticals, Inc., a biotechnology company developing antiviral therapies, announced today that it has licensed the exclusive worldwide rights to novel Hepatitis C Virus (HCV) technology from Stanford University. This technology, discovered in the lab of Stanford scientist and Eiger founder Dr. Jeffrey Glenn, M.D., Ph.D., is focused on a variety of novel targets, including key features of NS4B, a non-structural protein in the HCV genome, which binds to HCV-RNA and is required for viral replication.
Oncology

PEAK Surgical Announces First Use Of PEAK PlasmaBlade(TM) In Europe

PEAK Surgical, Inc., announced the first use of its PEAK(R) Surgery System by surgeons in the European Union, where the innovative tissue dissection system received its CE Mark in January. Dr. Raul Pellini and Prof. Giuseppe Spriano, ear, nose and throat (ENT) surgeons at Istituti Fisioterapici Ospitalieri (National Cancer Institute) in Rome, performed head and neck surgeries in cancer patients using the PEAK PlasmaBlades(TM). Additionally, Prof. Spriano hosted a head and neck surgical international course on May 20-21 that also included a live surgery using the PlasmaBlade. "The PlasmaBlades worked beautifully in the partial laryngectomy and parotid dissection we conducted, producing nearly bloodless procedures," said Dr. Pellini. "We are very keen for our ENT colleagues to evaluate these innovative devices as we expect that their patients will experience similar positive outcomes." "Like their colleagues in the United States, surgeons in Europe are providing positive feedback that the PlasmaBlade allows them to precisely cut tissue and control bleeding during a wide variety of surgical procedures without causing extensive collateral thermal damage to tissues," said John Tighe, president and chief executive officer of PEAK Surgical. "We expect to see continued uptake of the PEAK Surgery System in Europe, where we believe the PlasmaBlade could eventually be used in more than one million surgical procedures annually." The PEAK PlasmaBlade(TM) is a family of disposable, low-temperature surgical cutting and coagulation devices that offer the exacting control of a scalpel and the bleeding control of traditional electrosurgery without the extensive collateral damage. The PlasmaBlade is part of the PEAK(R) Surgery System, which also includes the PULSAR(R) Generator. The generator provides pulsed plasma radiofrequency energy to the PlasmaBlade to incise tissue and control bleeding. In the United States, the PEAK Surgery System is cleared for use in general, plastic and reconstructive, ENT, gynecologic, orthopedic, arthroscopic, spinal and neurological surgical procedures. It was launched in the United States in July 2008 and has been used by U.S. surgeons on more than 1,000 patients, including general, gynecologic, and plastic and reconstructive surgeries. PEAK Surgical has initiated a series of clinical studies, called the PRECISE Studies (Pulsed Plasma Radiofrequency Energy to ReduCe Thermal Injury and Improve Surgical HEaling), to evaluate the use of the PEAK Surgery System in plastic and reconstructive, gynecologic and oncologic surgery. Initial study results are expected later this year. Benefits of the PlasmaBlade and PULSAR Generator For decades, surgeons have relied on scalpels to cut skin and delicate tissues and have used electrosurgical devices to cut and coagulate fat and other thicker, tougher tissues. Although scalpels precisely cut tissue, they do not control bleeding. Electrosurgical devices, on the other hand, cut efficiently and control bleeding but cause extensive thermal damage to surrounding tissue. In cases where the risk of collateral damage or scarring from electrosurgery is considered to be unacceptable, surgeons must use both a traditional scalpel for cutting and an electrosurgical device for coagulation. The PlasmaBlade family of devices offers the precision of a scalpel and the bleeding control of a traditional electrosurgery device in a single surgical instrument. The PlasmaBlade family includes the PlasmaBlade 4.0, which is designed to be used to cut through all types of soft tissue, including skin, fat and muscle; the PlasmaBlade Needle, which has a fine needlepoint tip and is specifically designed for ultra-precise surgical procedures; and the PlasmaBlade EXT, which is designed for use in surgical procedures requiring an extended-reach tip. Unlike most radiofrequency-based surgical products that use continuous voltage waveforms to cut tissue, the PULSAR Generator supplies pulsed plasma radiofrequency energy to the PlasmaBlade to incise tissue and control bleeding. Because the radiofrequency energy is provided through short on-and-off pulses via a highly insulated cutting electrode, the PlasmaBlade cuts at half the average temperature of a conventional electrosurgery device and can be as low as 50 degrees Centigrade. This temperature reduction results in significantly less damage to surrounding tissues compared to traditional electrosurgery. The PlasmaBlade is also able to dissect tissue in a completely submerged surgical field, another shortcoming of traditional electrosurgical devices. Preclinical results have demonstrated that the PlasmaBlade is associated with effective bleeding control, minimal thermal tissue injury, reduced scarring and inflammation, and improved surgical incision healing and strength compared with traditional electrosurgical or electrocautery devices. In addition, preclinical results have demonstrated that the PlasmaBlade is associated with improved fascia incision healing in an in vivo model compared to the use of traditional electrosurgery. The PlasmaBlade demonstrated reductions in acute thermal injury depth, healed fascial scar width and inflammatory response with greater healed wound strength. PEAK Surgical"s pulsed plasma-mediated discharges and electrode insulation techniques were originally invented at the Hansen Experimental Physics Laboratory and Department of Ophthalmology at Stanford University and developed by PEAK Surgical. About PEAK Surgical, Inc. PEAK Surgical, Inc. is a medical device company that has developed the PEAK(R) Surgery System, a new tissue dissection system based on a proprietary technology that represents an important advance in radiofrequency surgical technologies. The PEAK Surgery System consists of the PEAK PlasmaBlade(TM), a family of disposable cutting devices that offer the exacting control of a scalpel and the bleeding control of traditional electrosurgery without extensive collateral damage, and the PULSAR(R) Generator, which supplies pulsed plasma radiofrequency energy to the PlasmaBlade. The PEAK Surgery System is cleared for use in general, plastic and reconstructive, ENT, gynecologic, orthopedic, arthroscopic, spinal and neurological surgical procedures in the United States, and for use in general surgery in the EU. PEAK Surgical, Inc


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):